Search

Displaying results 3071 - 3080 of 7607 in total
  1. Drug

    Brepocitinib

    go.drugbank.com/drugs/DB15003
    ApprovedInvestigational

    [L64097] Brepocitinib is not recommended in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs. … Brepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults.

  2. Drug

    Silver sulfadiazine

    go.drugbank.com/drugs/DB05245
    ApprovedInvestigationalVet approved

    Silver sulfadiazine is a sulfa derivative topical antibacterial used primarily on second- and third-degree burns.

  3. Drug

    Grazoprevir

    go.drugbank.com/drugs/DB11575
    Approved

    Grazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). … Approved in January 2016 by the FDA, Zepatier is indicated for the treatment of HCV genotypes 1 and 4 with or without [DB00811] depending on the the presence of resistance associated amino acid substitutions

  4. Drug

    Prostaglandin G2

    go.drugbank.com/drugs/DB03866
    Experimental

    A cyclic endoperoxide intermediate produced by the action of CYCLOOXYGENASE on ARACHIDONIC ACID. It is further converted by a series of specific enzymes to the series 2 prostaglandins. [PubChem]

  5. Drug

    AS1409

    go.drugbank.com/drugs/DB05182
    Investigational

    It is developed by Antisoma is in a phase I of clinical trial for the treatment of renal cancer and melanoma. … AS1409 is a genetically engineered fusion protein made up of two distinct components. One is the cytokine IL12, which has anti-cancer activity. The other is an antibody that targets tumours.

  6. Drug

    Trilaciclib

    go.drugbank.com/drugs/DB15442
    ApprovedInvestigational

    [A229313] Trilaciclib was granted FDA approval on 12 February 2021.[L31823] … Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing

    Categories: MATE 2-K Inhibitors
  7. Drug

    Atovaquone

    go.drugbank.com/drugs/DB01117
    ApprovedInvestigational

    Atovaquone is a hydroxynaphthoquinone, or an analog of ubiquinone, that has antimicrobial and antipneumocystis activity. It is being used in antimalarial protocols.

  8. Drug

    Nisoxetine

    go.drugbank.com/drugs/DB09186
    Experimental

    It was originally investigated as an antidepressant but has no current clinical applications aside from being a research standard SNRI. … It has been used to research obesity and energy balance, and exerts some local analgesia effects.

  9. Drug

    Remibrutinib

    go.drugbank.com/drugs/DB16852
    ApprovedInvestigational

    The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria.

  10. Drug

    GPI-1485

    go.drugbank.com/drugs/DB05814
    Investigational

    GPI 1485 is a product candidate that belongs to a class of small molecule compounds called neuroimmunophilin ligands. … In preclinical experiments, neuroimmunophilin ligands have been shown to repair and regenerate damaged nerves without affecting normal, healthy nerves.